Predisposition and Transition Mechanisms From Arterial Hypertension to Heart Failure (Hypercare)
Genetics and Genomics of Hypertension Associated With Microinflammation, Oxydative Stress, Chronic Renal Disease and Heart Failure (A2-B2-B3)
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljerad beskrivning
In all index patients and recruited family members, recorded data will include the following :
- Past medical history, drug history and family history
- Physical examination
- Height, weight, waist and hip circumference
- Cardiac examination
- Vascular examination
- Blood pressure
- Plasma and urine samples
- Body composition (DEXA)
- Tissue Doppler imaging
Studietyp
Studietyp
Inskrivning (Faktisk)
Inskrivning
Fas
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Alsace
-
Strasbourg, Alsace, Frankrike, 67000
- Centre D'Investigation Clinique de Strasbourg
-
-
Lorraine
-
Nancy, Lorraine, Frankrike, 54000
- Hopital Brabois Adulte
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
index patient :
- Caucasian patients of either sex who were diagnosed to have essential hypertension (as defined below) before the age of 50 y.
- The index patient should not be older than 60 years at the time of enrolment.
Definition of hypertension for the index patient:
- If untreated: Systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 95 mmHg.
- If already on treatment: Treatment with more of 2 different antihypertensive drugs at the time of enrolment.
- At least three first degree relatives of whom at least one should be affected and at least one be from a different generation (parents or offspring aged 18 years or above) must be willing to participate in the family study. For definition of hypertension in relatives of the index patient see below.
- Written informed consent
family
- at least three other first degree relatives must be willing to participate in the family study:
- at least one first-degree relative must be affected with diagnosis of hypertension made before age of 50 years AND
- at least one first degree relative must be from a different generation (offspring or parents).
Exclusion Criteria:
index patient :
- Any known form of secondary hypertension, including sleep apnoea syndrome
- Any known previous clinical complications of hypertension (angina, MI, stroke, TIA, peripheral artery disease) at any time
- Any known renal disease, including GFR < 60 mL/min as estimated by the abbreviated MDRD formula, or kidney stones
- Kidney or other organ transplantation
- Type 1 diabetes mellitus
- Heart failure stage D (AHA/ACC criteria)
- Any malignant concomitant diseases or history of malignant diseases within the last five years, with exception of treated squamous skin cancer or basalioma
- Clinical or laboratory signs of acute infection, especially urinary tract infection
- Systemic inflammatory diseases, such as autoimmune diseases, connective tissue diseases or collagenoses.
- Steroids or any other immunosuppressive drug
- Severe known liver disease (ALT or gamma-GT above three-fold of upper normal limit)
- Current alcohol consume of more than 21 drinks/week (1 drink = a bottle (0,33 l) beer, a glass (0,2 l) of wine, or 4 cl = 40 ml of spirit (40%)) or drug abuse such as cocaine
family
- any organ transplantation
- any malignant concomitant disease
- acute infection
- systemic inflammatory disease
- severe liver disease
- current alcohol or drug abuse
Studieplan
Hur är studien utformad?
Designdetaljer
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Övrig: NOE
multicentric family-based cohort.
prospective and transversal study
|
blood and urine sample
|
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
genetic biomarkers
Tidsram: time point 1 : first day ; Time point
|
time point 1 : first day ; Time point
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
oxidative stress markers
Tidsram: time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years
|
time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years
|
|
microinflammation markers
Tidsram: time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years
|
time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years
|
|
renal function and damage markers
Tidsram: time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years
|
time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years
|
|
cardiac and large artery growth, remodelling dysfunction and failure markers
Tidsram: time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years
|
time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years
|
Samarbetspartners och utredare
Sponsor
Sponsor
Samarbetspartners
Samarbetspartners
Utredare
Utredare
- Huvudutredare: faiez ZANNAD, Pr, Central Hospital, Nancy, France
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Studiestart
Primärt slutförande (Faktisk)
Primärt slutförande
Avslutad studie (Faktisk)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
Andra studie-ID-nummer
- HYPERCARE(english v. 1.0)JRPB3
- Cpp : 07.11.11
- Dgs: 2007-0537
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .